TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03359408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia Care Management (DCM)
Description: A specialised discharge management, based on Dementia Care Management (DCM; Thyrian et al. 2017, Eichler, Thyrian, Fredrich et al. 2014, Eichler, Thyrian, Dreier et al. 2014, Dreier et al. 2016, ) will be applied to subjects with cognitive impairment. Specifically qualified will conduct comprehensive data assessments during the hospital stay, assess recommendations at discharge and assess unmet needs at home. Supported by a a computerized Intervention Management (IMS) and in close cooperation with the discharging hospital, treating physicians and other care providers, they will develop, implement and monitor a treatment and care plan. Interventional home visits will take place at the participants homes.
Study: NCT02603289

Intervention type: DEVICE
Intervention: Invisalign

Intervention type: DEVICE
Intervention: Invisalign

Intervention type: DEVICE
Intervention: Invisalign
Study: NCT01383174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support Program
Description: * Work with a trained counselor who is a breast cancer survivor~* Meet 8 times in-person over the 8 week program with the counselor~* Counselor helps participant develop a personalized support program to help her improve her quality of life~* Receives information on breast cancer, its treatments, and stress management
Study: NCT03440840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Application of a small electrical current (1-2 mA) across the head.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Application of a small electrical current (1-2 mA) across the head.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Cognitive Training
Description: Use of computer-delivered games or exercises with the goal of improving cognitive performance.
Study: NCT03953157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02181127

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-only Bionic Pancreas
Description: A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon-only Bionic Pancreas
Description: A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
Study: NCT00299546

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab 50 mg
Description: SC injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: SC injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: SC injections
Study: NCT05809440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20-minute mindful breathing session
Description: A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
Study: NCT00726440

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigator®
Description: Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigator®
Description: Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will have their usual follow up with self-monitoring blood glucose
Study: NCT03324802

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: hypofractionated radiation therapy
Study: NCT01887132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00567086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TEZAMPANEL
Description: Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
Study: NCT03440840

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based Cognitive Training
Description: Use of computer-delivered games or exercises with the goal of improving cognitive performance.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Watching Educational Videos
Description: Watching educational videos and answering questions about them
Study: NCT00644020

Intervention type: DRUG
Intervention: mitomycin, Fluorouracil
Description: All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.

Intervention type: DRUG
Intervention: mitomycin, Fluorouracil
Description: All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.

Intervention type: DRUG
Intervention: mitomycin, Fluorouracil
Description: All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.

Intervention type: DRUG
Intervention: mitomycin, Fluorouracil
Description: All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
Study: NCT03612778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: Prescription of a meal plan based on unrefined plant-based foods supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a low-fat, unrefined, plant-based nutritional pattern.
Study: NCT00567086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZAMPANEL
Description: Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZAMPANEL
Description: Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
Study: NCT03612778

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Prescription of a meal plan based on Mediterranean diet pattern supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a Mediterranean nutritional pattern.
Study: NCT03413124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGL-3196 Tablet
Description: MGL-3196 in Tablet form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGL-3196 Tablet
Description: MGL-3196 in Tablet form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGL-3196 Capsule
Description: MGL-3196 in Capsule form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGL-3196 Capsule
Description: MGL-3196 in Capsule form
Study: NCT02721602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Preventing Diabetes Together
Description: Families in the intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
Study: NCT03997669

Intervention type: OTHER
Intervention: Collection of pleural effusion
Description: Detection of pleural effusion

Intervention type: OTHER
Intervention: Collection of pleural effusion
Description: Detection of pleural effusion
Study: NCT03515824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1697
Description: Administered by IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1697
Description: Administered by IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1697
Description: Administered by IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1697
Description: Administered by IV infusion on Day 1 of each 21-day cycle
Study: NCT04470635

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Saliva sample collection

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Saliva sample collection
Study: NCT00567086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZAMPANEL
Description: Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
Study: NCT02172144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL solution for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1744 CL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (Avalox®)
Study: NCT00497757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: enriched hematopoetic stem cell infusion
Description: Enriched Hematopoetic Stem Cell Infusion
Study: NCT02864563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: * Blood sample at diagnosis to evaluate MYCN amplification in plasma.~* In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up.
Study: NCT02380287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized monoclonal antibody against human IL-17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized monoclonal antibody against human IL-17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized monoclonal antibody against human IL-17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized monoclonal antibody against human IL-17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized monoclonal antibody against human IL-17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized monoclonal antibody against human IL-17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized monoclonal antibody against human IL-17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized monoclonal antibody against human IL-17
Study: NCT02426840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose vitamin D and calcium
Description: participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal dose vitamin D and calcium
Description: participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
Study: NCT00370747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecabet
Description: ophthalmic solution 3.70%
Study: NCT01683539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Thinking Skills for Work Program
Description: The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Cognitive Skills for Work Program
Description: The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
Study: NCT02303093

Intervention type: BIOLOGICAL
Intervention: Octagam IVIG 5% or 10%
Description: Octagam IVIG 5% or 10%

Intervention type: BIOLOGICAL
Intervention: Panzyga
Description: Panzyga
Study: NCT00539994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retapamulin
Description: 200mg BID retapamulin 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin
Description: 200mg BID retapamulin 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg BID placebo 5 days
Study: NCT04579471

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 IgG
Description: Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 IgG
Description: Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 IgG
Description: Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies
Study: NCT02214641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient, Empowered, Active Living with Diabetes
Description: Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive a total of 10-16 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the REAL Diabetes intervention protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Control
Description: Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose. The packet of materials will be delivered in an initial home visit. Follow-up phone calls will occur at approximately two week intervals to inquire whether participants have reviewed specific sections of the intervention materials, and clarify information included in the packet.
Study: NCT03424538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: 5-week-long intervention, physiotherapy, stretching, walking preparation, strengthening
Study: NCT00370747

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01289899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-A-657
Description: 120, 360mg or placebo 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-A-657
Description: 120, 360mg or placebo 7days
Study: NCT01125956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned a peer counselor
Description: Dyads will be given $20 per month if they have contact 4 or more times during a month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
Study: NCT00654381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Description: 5 mg/daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Description: 10 mg/daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: voglibose placebo
Description: three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 1356 placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voglibose
Description: 0.6 mg/daily
Study: NCT02189187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Study: NCT00832208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B (Ambisome)
Description: 21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (Ambisome)
Description: liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
Study: NCT03604055

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobronchial hamartomas treatment
Description: General anesthesia was administered by an intravenous anesthesia technique. Patients were intubated with a rigid bronchoscope. Debulking procedures were performed by mechanical tumor resection (MTR) using the tip of the rigid bronchoscope, rigid pliers or argon plasma coagulation assisted MTR or cryorecanalization or electrocautery - snare probe. An innovation of our study was that cryotherapy was performed in the regions where the lesions originated after debulking
Study: NCT01067352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH)
Description: Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
Study: NCT03448003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer Prevention
Description: Attend IO prevention program
Study: NCT00365599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suberoylanilide hydroxamic acid (SAHA, Vorinostat)
Description: Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
Study: NCT03448003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00723606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone mesylate
Description: The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular haloperidol
Description: The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
Study: NCT03052582

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk type

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk type
Study: NCT00826267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: lapatinib tablets 1500 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
Study: NCT02623803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo D5W
Study: NCT05508529

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chaga Mushroom
Description: Effect of chaga on immune/mood support

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Algae Extract
Description: Effect of algae extract on immune/mood support

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black Cumin Seed Oil
Description: Effect of black cumin seed oil on immune/mood support

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black Cumin Seed Oil + Astaxanthin
Description: Effect of Black Cumin Seed Oil + Astaxanthin blend on immune/mood support

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black Cumin Seed Oil + Omega 3
Description: Effect of Black Cumin Seed Oil + Omega3 blend on immune/mood support

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT03341130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Repositioning Splint
Description: The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Oral Appliance
Description: Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
Study: NCT00365599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate (Tamoxifen)
Description: Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).